Evaluation of the presence and severity of menopausal symptoms among postmenopausal women screened for the metabolic syndrome

Abstract

In this postmenopausal sample, severity of menopausal symptoms correlated to abdominal obesity, mood and other personal aspects.

Evaluation of the Effectiveness of Health Education on Menopause Symptoms and Knowledge and Attitude in Terms of Menopause

“…Chou et al [16] also reported sleep problems as the fourth most common symptom. Depressive mood was added to these symptoms in some studies [17][18][19]. Another study reported that vasomotor symptoms such as hot flashes are the most common in the menopausal period [20].…”

Increased mood symptoms in postmenopausal women related to the polymorphism rs743572 of the CYP17 A1 gene

“…Indeed, this is true as menopausal estrogens are synthesized by aromatization of androgens in the fat tissue and this phenomena explains differences observed in studies addressing the duration and the intensity of symptoms after the menopause onset [23,24]. In this sense, although the primary aim of the original cohort was to screen for the METS, prevalence of the METS or of its components did not vary in accordance to the genotypes of the studied CYP polymorphism, nor did menopausal symptom intensity vary according to genotype after stratifying for the presence of the METS or its components; despite the fact that the same cohort presented more severe menopausal symptoms related to obesity [12].…”

“…We previously reported data of a cross-sectional study carried out from December 2011 to June 2012 at the Institute of Biomedicine of the Medical Faculty of the Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, regarding menopausal and depressive symptoms among women screened for the metabolic syndrome (METS) [12]. Through newspaper advertisement, a total of 204 natural postmenopausal women (40-65 years) were recruited who were not on menopausal hormone therapy (MHT), phytoestrogens or drugs intended to decrease lipid levels.…”

NJK14013, a novel synthetic estrogen receptor-α agonist, exhibits estrogen receptor-independent, tumor cell-specific cytotoxicity

“…Accordingly, there have been numerous efforts to develop compounds capable of modulating ER-mediated signaling pathways, and several selective estrogen receptor modulators (SERMs) and aromatase inhibitors have been approved. To date, the major clinical applications of SERMs are in the treatment of ER-positive breast cancer and the prevention and treatment of postmenopausal symptoms caused by the low levels of estrogens that accompany osteoporosis (1)(2)(3). In addition, recent studies suggest the possible use of SERMs as neuroprotective agents (4,5).…”